Business Context and Reporting Period
This Form 8-K was filed by AmerisourceBergen Corporation (now Cencora, Inc.) on December 13, 2002. The report discloses a material corporate event involving the acquisition of US Bioservices Corporation, a national pharmaceutical service provider specializing in high-cost, complex therapies and reimbursement support.
Key Financial Metrics
The filing details the financial structure of the acquisition but does not provide the Company's consolidated revenue, profit, cash flow, or liquidity metrics for the reporting period.
- Base Purchase Price: Approximately $160,000,000 (including assumed debt).
- Contingency Payments: Up to a maximum of $30,000,000.
- Equity Consideration: Approximately 2.4 million shares of common stock to be issued upon closing.
- Adjustments: Both base price and contingency payments are subject to potential adjustments at closing.
Material Changes
The primary material change is the execution of a definitive agreement to acquire US Bioservices Corporation. This transaction represents a strategic expansion into the management of complex therapies. No comparative financial data or changes in prior period performance are provided in this specific filing.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or a discussion of specific risks and contingencies beyond the standard disclosure that the purchase price is subject to closing adjustments. The transaction is contingent upon the closing of the agreement.
Investor Verification Checklist
- Verify the final closing date and whether the transaction was completed as announced.
- Confirm the final purchase price after any closing adjustments to the base price and contingency payments.
- Review the impact of the 2.4 million share issuance on existing shareholder dilution.
- Assess the specific amount of debt assumed from US Bioservices Corporation within the $160 million base price.